• PDF: Delivered by email usually within 12 to 24 UK business hours.

Netherlands In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Netherlands In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Netherlands In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the Netherlands In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Netherlands

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in Netherlands.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in Netherlands.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in the Report
    • 3.1 In Vitro Diagnostics Devices
    • 3.2 Clinical Chemistry Test Reagents
      • 3.2.1 Laboratory Reagents
      • 3.2.2 Clinical Chemistry Calibrators and Controls
      • 3.2.3 Clinical Chemistry Rapid Tests
    • 3.3 Immunochemistry Test Reagents
      • 3.3.1 Disease Specific Markers
      • 3.3.2 Disease Specific Test Reagents
      • 3.3.3 Drug Related Testing Reagents
      • 3.3.4 Hormone Related Testing Reagents
      • 3.3.5 Immunochemistry Calibrators and Controls
      • 3.3.6 Immunochemistry Rapid Tests
    • 3.4 Blood Test Reagents
      • 3.4.1 Hematology Test Reagents
      • 3.4.2 Hemostasis Test Reagents
      • 3.4.3 Tissue Typing Reagents
      • 3.4.4 Monoclonal Antibodies
      • 3.4.5 Cytokines and Immunomodulators
      • 3.4.6 Histology and Cytology Reagents
    • 3.5 Microbiology Test Reagents
      • 3.5.1 Bacteriology Test Reagents
      • 3.5.2 Microbiology Calibrators and Controls
      • 3.5.3 Microbiology Rapid Tests
    • 3.6 Infectious Immunology Test Reagents
      • 3.6.1 Bacteriology
      • 3.6.2 Virology
      • 3.6.3 Parasitology
      • 3.6.4 Infectious Immunology Calibrators and Controls
      • 3.6.5 Infectious Immunology Rapid Tests
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
    • 4.3 Healthcare Policy
      • 4.3.1 Health Insurance Act
      • 4.3.2 Healthcare Allowance Act
      • 4.3.3 The Exceptional Medical Expenses Act
  • 5 Regulation System
    • 5.1 Medical Equipment Approval Process
      • 5.1.1 Classification of Medical Devices
      • 5.1.2 Conformity Assessment Process
    • 5.2 Post Market Surveillance (PMS)
  • 6 Pricing and Reimbursement
    • 6.1 Pricing and Reimbursement in Netherlands
  • 7 Distribution Structure
    • 7.1 Distribution Structure in Netherlands
  • 8 In Vitro Diagnostics In Netherlands
    • 8.1 In Vitro Diagnostics Cross Country Comparison (2000-2012)
    • 8.2 In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), 2000-2012
    • 8.3 In Vitro Diagnostics, Netherlands, Company Share (2006-2007)
  • 9 Blood Test Reagents In Netherlands
    • 9.1 Blood Test Reagents Overall Revenue (2000-2012)
      • 9.1.1 Haematology Test Reagents Overall Revenues (2000-2012)
      • 9.1.2 Hemostasis Test Reagents Overall Revenues (2000-2012)
    • 9.2 Blood Test Reagents Distribution Share (2006-2007)
    • 9.3 Blood Test Reagents, Netherlands, Company Share (2006-2007)
  • 10 Clinical Chemistry Test Reagents In Netherlands
    • 10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012)
    • 10.2 Clinical Chemistry Test Reagents Distribution Share (2006-2007)
    • 10.3 Clinical Chemistry Test Reagents, Netherlands, Company Share (2006-2007)
  • 11 Genetic Test Reagents In Netherlands
    • 11.1 Genetic Test Reagents Overall Revenue (2000-2012)
    • 11.2 Genetic Test Reagents Distribution Share (2006-2007)
    • 11.3 Genetic Test Reagents, Netherlands, Company Share (2006-2007)
  • 12 Immunochemistry Test Reagents In Netherlands
    • 12.1 Immunochemistry Test Reagents Overall Revenue (2000-2012)
      • 12.1.1 Disease Specific Markers Overall Revenues (2000-2012)
      • 12.1.2 Disease Specific Test Reagents Overall Revenues (2000-2012)
      • 12.1.3 Drug Related Testing Reagents Overall Revenues (2000-2012)
      • 12.1.4 Hormone Related Testing Reagents Overall Revenues (2000-2012)
    • 12.2 Immunochemistry Test Reagents Distribution Share (2006-2007)
    • 12.3 Immunochemistry Test Reagents, Netherlands, Company Share (2006-2007)
  • 13 Infectious Immunology Test Reagents In Netherlands
    • 13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012)
      • 13.1.1 Virology Overall Revenues (2000-2012)
    • 13.2 Infectious Immunology Test Reagents Distribution Share (2006-2007)
    • 13.3 Infectious Immunology Test Reagents, Netherlands, Company Share (2006-2007)
  • 14 Instruments In Netherlands
    • 14.1 Instruments Overall Revenue (2000-2012)
    • 14.2 Instruments Distribution Share (2006-2007)
  • 15 Microbiology Test Reagents In Netherlands
    • 15.1 Microbiology Test Reagents Overall Revenue (2000-2012)
      • 15.1.1 Bacteriology Test Reagents Overall Revenues (2000-2012)
    • 15.2 Microbiology Test Reagents Distribution Share (2006-2007)
    • 15.3 Microbiology Test Reagents, Netherlands, Company Share (2006-2007)
  • 16 Self Testing In Netherlands
    • 16.1 Self Testing Overall Revenue (2000-2012)
    • 16.2 Self Testing Distribution Share (2006-2007)
    • 16.3 Self Testing, Netherlands, Company Share (2006-2007)
  • 17 F. Hoffmann-La Roche Ltd. Company Profile
    • 17.1 Company Overview
    • 17.2 Value Chain Analysis
      • 17.2.1 Manufacturing
      • 17.2.2 Product Development
      • 17.2.3 Sales and Marketing
  • 18 Abbott Laboratories Company Profile
    • 18.1 Company Overview
    • 18.2 Value Chain Analysis
      • 18.2.1 Manufacturing
      • 18.2.2 Product Development
      • 18.2.3 Sales and Marketing
      • 18.2.4 Abbott Laboratories Pipeline Products by Equipment Type
      • 18.2.5 Abbott Laboratories Pipeline Products by Development Stage
      • 18.2.6 Abbott Laboratories Pipeline Products by Therapy Area
      • 18.2.7 Abbott Laboratories Pipeline Products by Clinical Trials
      • 18.2.8 Abbott Laboratories Pipeline Products by News Summary
  • 19 bioMerieux S.A. Company Profile
    • 19.1 Company Overview
    • 19.2 Value Chain Analysis
      • 19.2.1 Manufacturing
      • 19.2.2 Product Development
      • 19.2.3 Sales and Marketing
  • 20 Beckman Coulter, Inc. Company Profile
    • 20.1 Company Overview
    • 20.2 Value Chain Analysis
      • 20.2.1 Manufacturing
      • 20.2.2 Product Development
      • 20.2.3 Sales and Marketing
    • 20.3 Beckman Coulter, Inc. Pipeline Products
      • 20.3.1 Beckman Coulter, Inc. Pipeline Products by Equipment Type
      • 20.3.2 Beckman Coulter, Inc. Pipeline Products by Development Stage
      • 20.3.3 Beckman Coulter, Inc. Pipeline Products by Therapy Area
      • 20.3.4 Beckman Coulter, Inc. Pipeline Products by News Summary
  • 21 Dade Behring Holdings, Inc. Company Profile
    • 21.1 Company Overview
      • 21.1.1 Dade Behring Holdings, Inc. Pipeline Products by Equipment Type
      • 21.1.2 Dade Behring Holdings, Inc. Pipeline Products by Development Stage
      • 21.1.3 Dade Behring Holdings, Inc. Pipeline Products by Therapy Area
      • 21.1.4 Dade Behring Holdings, Inc. Pipeline Products by News Summary
  • 22 Ortho-Clinical Diagnostics Inc. Company Profile
    • 22.1 Company Overview
  • 23 Adamas Instrumenten bv Company Profile
    • 23.1 Company Overview
  • 24 Agendia BV Company Profile
    • 24.1 Company Overview
  • 25 Euro-Diagnostica B.V. Company Profile
    • 25.1 Company Overview
  • 26 GELITA MEDICAL B.V. Company Profile
    • 26.1 Company Overview
  • 27 Kreatech Holding B.V. Company Profile
    • 27.1 Company Overview
  • 28 Nordic Immunological Laboratories Company Profile
    • 28.1 Company Overview
  • 29 Pharming Group N.V. Company Profile
    • 29.1 Company Overview
      • 29.1.1 Pharming Group N.V. Pipeline Products by Equipment Type
      • 29.1.2 Pharming Group N.V. Pipeline Products by Development Stage
      • 29.1.3 Pharming Group N.V. Pipeline Products by Therapy Area
      • 29.1.4 Pharming Group N.V. Pipeline Products by News Summary
  • 30 Qiagen N.V. Company Profile
    • 30.1 Company Overview
    • 30.2 Qiagen N.V. Pipeline Products
      • 30.2.1 Qiagen N.V. Pipeline Products by Equipment Type
      • 30.2.2 Qiagen N.V. Pipeline Products by Development Stage
      • 30.2.3 Qiagen N.V. Pipeline Products by Therapy Area
      • 30.2.4 Qiagen N.V. Pipeline Products by News Summary
  • 31 Vital Scientific B.V. Company Profile
    • 31.1 Company Overview
  • 32 Financial Deals Landscape
    • 32.1 Partnerships
      • 32.1.1 Luminex Signs an Agreement with ViroNovative
  • 33 Recent Developments
    • 33.1 Product News
      • 33.1.1 Oct 28, 2008: OraSure Technologies Files for FDA Approval of OraQuick Rapid Hepatitis C Test
      • 33.1.2 Aug 19, 2008: QIAGEN Unveils Diagnostic Assay in the EU to Detect Genetic Variation Causing Adverse Reactions In AIDS Patients
  • 34 Appendix
    • 34.1 Global Markets Direct Research Methodology
    • 34.2 Coverage
    • 34.3 Secondary Research
    • 34.4 Primary Research
    • 34.5 Models
    • 34.6 Forecasts
    • 34.7 Expert Panels
    • 34.8 Currency Conversion
    • 34.9 Contact Us
    • 34.10 Disclaimer
  • 1.1 List of Tables
    • Table 1: Doctors by Specialty in Netherlands, 2000-2006
    • Table 2: Hospital Wards by Type in Netherlands, 2000-2006
    • Table 3: In Vitro Diagnostics Cross Country Comparison (2000-2012)
    • Table 4: In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), 2000-2012
    • Table 5: In Vitro Diagnostics, Netherlands, Portfolio Analysis, 2000-2012
    • Table 6: In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 7: In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 8: In Vitro Diagnostics, Netherlands Company, Share by Revenue ($ mn), 2006-2007
    • Table 9: Blood Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 10: Blood Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 11: Haematology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 12: Haematology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 13: Hemostasis Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 14: Hemostasis Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 15: Blood Test Reagents, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 16: Blood Test Reagents, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 17: Clinical Chemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 18: Clinical Chemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 19: Clinical Chemistry Test Reagents, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 20: Clinical Chemistry Test Reagents, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 21: Genetic Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 22: Genetic Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 23: Genetic Test Reagents, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 24: Genetic Test Reagents, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 25: Immunochemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 26: Immunochemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 27: Disease Specific Markers, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 28: Disease Specific Markers, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 29: Disease Specific Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 30: Disease Specific Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 31: Drug Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 32: Drug Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 33: Hormone Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 34: Hormone Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 35: Immunochemistry Test Reagents, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 36: Immunochemistry Test Reagents, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 37: Infectious Immunology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 38: Infectious Immunology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 39: Virology, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 40: Virology, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 41: Infectious Immunology Test Reagents, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 42: Infectious Immunology Test Reagents, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 43: Instruments, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 44: Instruments, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 45: Instruments, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 46: Microbiology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 47: Microbiology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 48: Bacteriology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Table 49: Bacteriology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Table 50: Microbiology Test Reagents, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 51: Microbiology Test Reagents, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 52: Self Testing, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Table 53: Self Testing, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Table 54: Self Testing, Netherlands, Distribution Share by Revenue ($mn), 2006-2007
    • Table 55: Self Testing, Netherlands, Company Share by Revenue ($ mn), 2006-2007
    • Table 56: Abbott Laboratories Pipeline Products by Equipment Type
    • Table 57: Abbott Laboratories Pipeline Products By Development Stage
    • Table 58: Abbott Laboratories Pipeline Products By Therapy Area
    • Table 59: Abbott Laboratories Pipeline Products By Clinical Trials
    • Table 60: Abbott Laboratories Pipeline Products By News Summaries
    • Table 61: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 62: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 63: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 64: Beckman Coulter, Inc. Pipeline Products By News Summaries
    • Table 65: Dade Behring Holdings, Inc. Pipeline Products by Equipment Type
    • Table 66: Dade Behring Holdings, Inc. Pipeline Products by Development Stage
    • Table 67: Dade Behring Holdings, Inc. Pipeline Products By Therapy Area
    • Table 68: Dade Behring Holdings, Inc. Pipeline Products By News Summaries
    • Table 69: Pharming Group N.V. Pipeline Products by Equipment Type
    • Table 70: Pharming Group N.V. Pipeline Products by Development Stage
    • Table 71: Pharming Group N.V. Pipeline Products By Therapy Area
    • Table 72: Pharming Group N.V. Pipeline Products By News Summaries
    • Table 73: Qiagen N.V. Pipeline Products by Equipment Type
    • Table 74: Qiagen N.V. Pipeline Products By Development Stage
    • Table 75: Qiagen N.V. Pipeline Products By Therapy Area
    • Table 76: Qiagen N.V. Pipeline Products By News Summaries
    • Table 77: Luminex Signs an Agreement with ViroNovative
    • Table 52: Currency Conversion from USD to Local Currency at 2007 Constant Rate
  • 1.2 List of Figures
    • Figure 1: Total Healthcare Expenditure in Netherlands, 2000 - 2006
    • Figure 2: Healthcare Financing Framework in Netherlands, 2005
    • Figure 3: Flowchart for Classification of Non-invasive Devices in Netherlands, 2007
    • Figure 4: Flowchart for Classification of Invasive Devices in Netherlands, 2007
    • Figure 5: Flowchart for Classification of Invasive Devices in Netherlands, 2007
    • Figure 6: Flowchart for Classification of Invasive Devices in Netherlands, 2007
    • Figure 7: Flowchart for Classification of Invasive Devices in Netherlands, 2007
    • Figure 8: Flowchart for Classification of Active Devices in Netherlands, 2007
    • Figure 9: Flowchart for Classification of Active Devices in Netherlands, 2007
    • Figure 10: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Netherlands, 2007
    • Figure 11: Conformity Assessment of Class-I Medical Devices in Netherlands, 2007
    • Figure 12: Conformity Assessment of Class-IIa Medical Devices in Netherlands, 2007
    • Figure 13: Conformity Assessment of Class-IIb Medical Devices in Netherlands, 2007
    • Figure 14: Conformity Assessment of Class-III Medical Devices in Netherlands, 2007
    • Figure 15: In Vitro Diagnostics Cross Country Comparison (2000-2012)
    • Figure 16: In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), 2000-2012
    • Figure 17: In Vitro Diagnostics, Netherlands, Portfolio Analysis, 2000-2012
    • Figure 18: In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 19: In Vitro Diagnostics, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 20: In Vitro Diagnostics, Netherlands, Company Share (%), 2007
    • Figure 21: Blood Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 22: Blood Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 23: Haematology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 24: Haematology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 25: Hemostasis Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 26: Hemostasis Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 27: Blood Test Reagents, Netherlands, Company Share (%), 2007
    • Figure 28: Clinical Chemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 29: Clinical Chemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 30: Clinical Chemistry Test Reagents, Netherlands, Company Share (%), 2007
    • Figure 31: Genetic Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 32: Genetic Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 33: Genetic Test Reagents, Netherlands, Company Share (%), 2007
    • Figure 34: Immunochemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 35: Immunochemistry Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 36: Disease Specific Markers, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 37: Disease Specific Markers, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 38: Disease Specific Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 39: Disease Specific Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 40: Drug Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 41: Drug Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 42: Hormone Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 43: Hormone Related Testing Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 44: Immunochemistry Test Reagents, Netherlands, Company Share (%), 2007
    • Figure 45: Infectious Immunology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 46: Infectious Immunology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 47: Virology, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 48: Virology, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 49: Infectious Immunology Test Reagents, Netherlands, Company Share (%), 2007
    • Figure 50: Instruments, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 51: Instruments, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 52: Microbiology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 53: Microbiology Test Reagents, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 54: Bacteriology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Historic, 2000-2007
    • Figure 55: Bacteriology Test Reagents, Netherlands, Revenues ($ mn) by Sub-Segment, Forecast, 2007-2012
    • Figure 56: Microbiology Test Reagents, Netherlands, Company Share (%), 2007
    • Figure 57: Self Testing, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2007
    • Figure 58: Self Testing, Netherlands, Revenue ($ mn) by Segment, Forecast, 2007-2012
    • Figure 59: Self Testing, Netherlands, Company Share (%), 2007
    • Figure 60: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 61: Abbott Laboratories Value Chain Analysis
    • Figure 62: Biomerieux Sa Value Chain Analysis
    • Figure 63: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 64: Global Markets Direct Methodology
+44 20 8816 8548

Ask a question about Netherlands In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2012

Enter the characters you see in the picture below
Captcha